Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study.
about
Osteoprotegerin levels in patients with severe mental disordersRelease of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review.Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.Skeleton and glucose metabolism: a bone-pancreas loop.Osteoprotegerin in Cardiometabolic Disorders.Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity.Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION studyRelation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic PatientsOsteoprotegerin as a marker of atherosclerosis in diabetic patients.Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes.Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.Obesity and inflammation: the effects of weight loss.Bone health as a function of adipokines and vitamin D pattern in elderly patients.Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes.The role of osteoprotegerin in cardiovascular disease.Regulation of adipocyte lipolysis.Bone-Derived Factors: A New Gateway to Regulate Glycemia.Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans.TNFRSF11B polymorphisms are associated with metabolic traits in Uyghur and Han ethnic groups.Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus.The association of insulin resistance with serum osteoprotegerin in obese adolescents.Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes.Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
P2860
Q24626094-201ABD8E-6C1E-4EA7-8FBE-1CB818527649Q33870787-A8F6B32F-18C1-4BD6-AE1A-FF5B53CD692CQ34399438-82CEF386-AA6E-4E9D-9EF9-90CDD7E23C56Q35250223-93FC85EE-E820-41DF-A211-0E3902088AB3Q35640787-3D2EB446-C5FA-49D9-B2DB-72FCA9D5A961Q35669454-780C7FF9-A480-4014-B503-4FEE5E0657C2Q35857588-8409F6FA-1255-49B4-98AF-56365FC7C06FQ35962096-DBDB8E30-8A22-40AC-9CE0-E64234B43AC0Q36582644-523E30ED-39A0-410D-BA28-1006FD9B8EB8Q37105254-DFB70D8A-EE17-4575-944E-3061D097D460Q37322445-B583C5F6-C45F-4D52-8205-F7109E6170FEQ37352219-55C523F4-05FA-4E7C-96C2-C1D9E2E6DB31Q37406678-F4AC38DC-C5DC-45F9-AFE6-FFAF39DEFF30Q37627672-9C14A410-4EC6-4A5C-830C-1918D04DC2D1Q37641079-F1E64195-6E07-4BCB-919B-BD9F5DCE33EAQ38056541-0B5C779C-0049-430A-B2CF-F7B1D665C279Q38215702-987C9F33-B5E1-48B1-9B20-101F0FD430C8Q39004609-3AA99766-4624-4634-B1C4-872E8A612C49Q39018695-9527B4F2-D44A-454E-8321-648961C18DE1Q44037048-436C7E55-86B1-440F-ABFA-21D92896EA8DQ44967650-085958F8-294A-4413-AF17-0EBAE10DA47BQ50972479-D1575B16-DECA-4E4B-91B1-5CA7E3632B39Q51375055-16A8330D-485D-4001-B855-25A3C2B16BCAQ55167292-CDEEB201-7CEA-4ECD-88B4-225B2549CD4F
P2860
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Osteoprotegerin in relation to ...... onal and interventional study.
@en
Osteoprotegerin in relation to ...... onal and interventional study.
@nl
type
label
Osteoprotegerin in relation to ...... onal and interventional study.
@en
Osteoprotegerin in relation to ...... onal and interventional study.
@nl
prefLabel
Osteoprotegerin in relation to ...... onal and interventional study.
@en
Osteoprotegerin in relation to ...... onal and interventional study.
@nl
P2093
P356
P1476
Osteoprotegerin in relation to ...... onal and interventional study.
@en
P2093
Bassem Habre
Cesar Yaghi
Myrna Germanos-Haddad
Roger Noun
Simon Khalife
Viviane Trak-Smayra
P304
P356
10.1530/EJE-07-0797
P577
2008-03-01T00:00:00Z